search
Back to results

Effects of Melatonin on Sleep, Ventilatory Control and Cognition at Altitude

Primary Purpose

Intermittent Hypoxia

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Melatonin
Placebo
Sponsored by
Robert L. Owens
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Intermittent Hypoxia focused on measuring Hypoxia, High Altitude, Melatonin, Neurocognitive

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy Males and Females
  • Age:18-65 years

Exclusion Criteria:

  • Sleep Disorders
  • Pregnant Females
  • Smokers (quit ≥ 1 year ago acceptable)
  • Cardiovascular, Pulmonary, Renal, Neurologic, Neuromuscular, or Hepatic Issues
  • Diabetes
  • Psychiatric disorder, other than mild depression
  • Recent exposure to altitude (>8000ft) in the last month or having slept at an altitude >6000ft in the last month

Sites / Locations

  • University of California, San Diego

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

No Intervention

Placebo Comparator

Experimental

Arm Label

Normoxia

Hypoxia and Placebo

Hypoxia and Melatonin

Arm Description

Participants will sleep in room air and receive no melatonin.

5mg placebo before sleep study

5mg melatonin before sleep study

Outcomes

Primary Outcome Measures

Change in Apnea Hypopnea Index
Measure of Sleep Apnea severity
Neurocognitive Scores
Reflex changes between conditions

Secondary Outcome Measures

Loop Gain
Measurement of breathing characteristics during sleep using a flow meter attached to a CPAP mask that allows the measurement of expiratory flow
Arousal Threshold
requirements for sleep arousal to occur
Sleep Efficiency
Time in bed divided by total sleep time
Total Antioxidant Status
Measurement taken from blood draw
Hypoxic Ventilatory Response
Change in breathing response while breathing low oxygen
Hypercapnic Ventilatory Response
Change in breathing response while breathing high carbon dioxide

Full Information

First Posted
January 3, 2018
Last Updated
August 13, 2019
Sponsor
Robert L. Owens
search

1. Study Identification

Unique Protocol Identification Number
NCT03588676
Brief Title
Effects of Melatonin on Sleep, Ventilatory Control and Cognition at Altitude
Official Title
Effects of Melatonin on Sleep, Ventilatory Control and Cognition at Altitude
Study Type
Interventional

2. Study Status

Record Verification Date
August 2019
Overall Recruitment Status
Completed
Study Start Date
January 10, 2018 (Actual)
Primary Completion Date
December 10, 2018 (Actual)
Study Completion Date
December 10, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Robert L. Owens

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Low oxygen at altitude causes pauses in breathing during sleep, called central sleep apnea. Central sleep apnea causes repeated awakenings and poor sleep. Low oxygen itself and the induced oxidative stress can damage mental function which is likely worsened by poor sleep. Reduced mental function due to low oxygen can pose a serious danger to mountain climbers. However there is also mounting evidence that even in populations of people that live at high altitudes and are considered adapted, low oxygen contributes to reductions in learning and memory. Therefore there is a serious need for treatments which may improve sleep, control of breathing and mental function during low oxygen.Therefore this study aims to determine how melatonin effects control of breathing, sleep and mental performance during exposure to low oxygen.
Detailed Description
Research has shown that exposure to low oxygen at altitude causes neurocognitive impairment (impaired mental processing, memory, attention, learning, etc). This impairment in cognitive performance poses a serious risk to mountain climbers and while it has traditionally been thought that people who live at high altitude have adapted to it, evidence shows there is still considerable damage to the brain and impairments in cognitive function of people who live and work at high altitude. As every cell in the body requires oxygen to survive and function, impairment in cognitive performance at altitude is thought mainly due to reduced oxygen availability to the central nervous system. However, low oxygen at altitude also causes unstable breathing during sleep which results in short periods where the brain stops sending the signal to breath, called central sleep apnea (CSA). During apneas (pauses in breathing) blood oxygen drops even lower and people typically wake up briefly and hyperventilate after apneas. Therefore at altitude people usually get less sleep, their sleep is broken with periods of wakefulness during the night and they experience repeated bouts of severe low blood oxygen levels. Sleep plays a critical role in how the brain repairs and also converts newly acquired information into long-term memory. Therefore broken and reduced sleep can impair cognitive performance, memory and learning. Repeated bouts of severe low oxygen also produces highly reactive molecules that cause damage to cells, called oxidative stress. Oxidative stress also prevents the brain from forming long-term memories and in severe cases (such as extremely high altitude and long duration exposure) can cause neurons in the brain to die. Therefore although sustained low oxygen at altitude likely impairs cognitive function, disturbed sleep and repeated bouts of severely low oxygen likely also contribute to causing brain damage and impaired cognitive performance. Melatonin is a hormone produced in the pineal gland of the brain during the night which signals to the brain that it is time to sleep. Melatonin is also a very powerful antioxidant which naturally helps to prevent damage in the body from oxidative stress. A study previously reported that melatonin taken 90 mins before bed at 4,300 m (14,200 ft) reduced the time taken to fall asleep, it reduced the number of times people woke up during sleep and improved cognitive performance the following day. However how melatonin caused these effects was not determined. Therefore this study aims to determine how melatonin affects ventilatory control, sleep and neurocognitive performance during sustained hypoxia.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Intermittent Hypoxia
Keywords
Hypoxia, High Altitude, Melatonin, Neurocognitive

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
randomized, placebo controlled, double blind, cross-over trial
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
39 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Normoxia
Arm Type
No Intervention
Arm Description
Participants will sleep in room air and receive no melatonin.
Arm Title
Hypoxia and Placebo
Arm Type
Placebo Comparator
Arm Description
5mg placebo before sleep study
Arm Title
Hypoxia and Melatonin
Arm Type
Experimental
Arm Description
5mg melatonin before sleep study
Intervention Type
Other
Intervention Name(s)
Melatonin
Intervention Description
5mg Melatonin
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
5mg Placebo capsule
Primary Outcome Measure Information:
Title
Change in Apnea Hypopnea Index
Description
Measure of Sleep Apnea severity
Time Frame
6 weeks
Title
Neurocognitive Scores
Description
Reflex changes between conditions
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
Loop Gain
Description
Measurement of breathing characteristics during sleep using a flow meter attached to a CPAP mask that allows the measurement of expiratory flow
Time Frame
6 weeks
Title
Arousal Threshold
Description
requirements for sleep arousal to occur
Time Frame
6 weeks
Title
Sleep Efficiency
Description
Time in bed divided by total sleep time
Time Frame
6 weeks
Title
Total Antioxidant Status
Description
Measurement taken from blood draw
Time Frame
6 weeks
Title
Hypoxic Ventilatory Response
Description
Change in breathing response while breathing low oxygen
Time Frame
6 weeks
Title
Hypercapnic Ventilatory Response
Description
Change in breathing response while breathing high carbon dioxide
Time Frame
6 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy Males and Females Age:18-65 years Exclusion Criteria: Sleep Disorders Pregnant Females Smokers (quit ≥ 1 year ago acceptable) Cardiovascular, Pulmonary, Renal, Neurologic, Neuromuscular, or Hepatic Issues Diabetes Psychiatric disorder, other than mild depression Recent exposure to altitude (>8000ft) in the last month or having slept at an altitude >6000ft in the last month
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Atul Malhotra, MD
Organizational Affiliation
Professor
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Naomi L Deacon, Ph.D.
Organizational Affiliation
Research Associate
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Pamela De Young
Organizational Affiliation
Research Associate
Official's Role
Study Chair
Facility Information:
Facility Name
University of California, San Diego
City
San Diego
State/Province
California
ZIP/Postal Code
92093
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Links:
URL
https://healthsciences.ucsd.edu/som/medicine/research/centers/sleep-research/research/active-studies/Pages/High-Altitude-and-Sleep.aspx
Description
Study Website

Learn more about this trial

Effects of Melatonin on Sleep, Ventilatory Control and Cognition at Altitude

We'll reach out to this number within 24 hrs